Cargando…

Astragaloside IV Protects against Isoproterenol-Induced Cardiac Hypertrophy by Regulating NF-κB/PGC-1α Signaling Mediated Energy Biosynthesis

We previously reported that Astragaloside IV (ASIV), a major active constituent of Astragalus membranaceus (Fisch) Bge protects against cardiac hypertrophy in rats induced by isoproterenol (Iso), however the mechanism underlying the protection remains unknown. Dysfunction of cardiac energy biosynthe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Suping, Tang, Futian, Yang, Yuhong, Lu, Meili, Luan, Aina, Zhang, Jing, Yang, Juan, Wang, Hongxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349820/ https://www.ncbi.nlm.nih.gov/pubmed/25738576 http://dx.doi.org/10.1371/journal.pone.0118759

Ejemplares similares

Calcium Sensing Receptor-Related Pathway Contributes to Cardiac Injury and the Mechanism of Astragaloside IV on Cardioprotection
por: Lu, Meili, et al.
Publicado: (2018)

Astragaloside IV Suppresses High Glucose-Induced NLRP3 Inflammasome Activation by Inhibiting TLR4/NF-κB and CaSR
por: Leng, Bin, et al.
Publicado: (2019)

Simvastatin Improves Cardiac Hypertrophy in Diabetic Rats by Attenuation of Oxidative Stress and Inflammation Induced by Calpain-1-Mediated Activation of Nuclear Factor-κB (NF-κB)
por: Han, Qianqian, et al.
Publicado: (2019)

Lycium barbarum polysaccharide attenuates cardiac hypertrophy, inhibits calpain-1 expression and inhibits NF-κB activation in streptozotocin-induced diabetic rats
por: Liu, Qianqian, et al.
Publicado: (2019)

Astragaloside IV Alleviates Brain Injury Induced by Hypoxia via the Calpain-1 Signaling Pathway
por: Meng, Yan, et al.
Publicado: (2022)

Astragaloside IV attenuates inflammatory response mediated by NLRP‐3/calpain‐1 is involved in the development of pulmonary hypertension
por: Sun, Yang, et al.
Publicado: (2020)

Astragaloside IV ameliorates peritoneal fibrosis by promoting PGC‐1α to reduce apoptosis in vitro and in vivo
por: Xie, Mingxia, et al.
Publicado: (2023)

Astragaloside IV Inhibits NF-κB Activation and Inflammatory Gene Expression in LPS-Treated Mice
por: Zhang, Wei-Jian, et al.
Publicado: (2015)

Rapamycin Attenuated Cardiac Hypertrophy Induced by Isoproterenol and Maintained Energy Homeostasis via Inhibiting NF-κB Activation
por: Chen, Xi, et al.
Publicado: (2014)

Astragaloside IV promotes pharmacological effect of Descurainia sophia seeds on isoproterenol-induced cardiomyopathy in rats by synergistically modulating the myosin motor
por: Liu, Xingkai, et al.
Publicado: (2022)

Astragaloside IV Relieves Atherosclerosis and Hepatic Steatosis via MAPK/NF-κB Signaling Pathway in LDLR(−/−) Mice
por: Zhang, Yifan, et al.
Publicado: (2022)

Astragaloside IV attenuates neuroinflammation and ameliorates cognitive impairment in Alzheimer’s disease via inhibiting NF-κB signaling pathway
por: He, Li, et al.
Publicado: (2023)

Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456
por: Wan, Jingjing, et al.
Publicado: (2023)

Astragaloside IV Alleviates the Myocardial Damage Induced by Lipopolysaccharide via the Toll-Like Receptor 4 (TLR4)/Nuclear Factor kappa B (NF-κB)/Proliferator-Activated Receptor α (PPARα) Signaling Pathway
por: Zhang, Xiaoyao, et al.
Publicado: (2019)

Anticancer effects and mechanisms of astragaloside-IV
por: Zhou, Liangxing, et al.
Publicado: (2022)

Pyrroloquinoline quinone attenuates isoproterenol hydrochloride-induced cardiac hypertrophy in AC16 cells by inhibiting the NF-κB signaling pathway
por: Wen, Junru, et al.
Publicado: (2020)

Research progress on the mechanism of astragaloside IV in the treatment of asthma
por: Yuan, Fanyi, et al.
Publicado: (2023)

Protective effect of Astragaloside IV on chronic intermittent hypoxia-induced vascular endothelial dysfunction through the calpain-1/SIRT1/AMPK signaling pathway
por: Zhao, Fang, et al.
Publicado: (2022)

Astragaloside IV attenuates IL-1β-induced intervertebral disc degeneration through inhibition of the NF-κB pathway
por: Tian, Yueyang, et al.
Publicado: (2022)

Astragaloside IV alleviates myocardial damage induced by type 2 diabetes via improving energy metabolism
por: Zhang, Zhen, et al.
Publicado: (2019)

Circular RNA expression in isoproterenol hydrochloride-induced cardiac hypertrophy
por: Yang, Ming-Hui, et al.
Publicado: (2020)

The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications
por: Li, Lin, et al.
Publicado: (2023)

Molecular mechanisms of astragaloside-IV in cancer therapy (Review)
por: Chen, Tianqi, et al.
Publicado: (2021)

Astragaloside IV alleviates heart failure by modulating Nrf-2
por: Feng, Wenxiao, et al.
Publicado: (2022)

Inhibition of miRNA-1-Mediated Inflammation and Autophagy by Astragaloside IV Improves Lipopolysaccharide-Induced Cardiac Dysfunction in Rats
por: Wang, Qiuning, et al.
Publicado: (2022)

The mechanism of astragaloside IV promoting sciatic nerve regeneration
por: Zhang, Xiaohong, et al.
Publicado: (2013)

Astragaloside IV alleviates placental oxidative stress and inflammation in GDM mice
por: Zhou, Ling, et al.
Publicado: (2020)

Astragaloside protects myocardial cells from apoptosis through suppression of the TLR4/NF-κB signaling pathway
por: Zhao, Yang, et al.
Publicado: (2018)

Astragaloside IV regulates NF-κB-mediated cellular senescence and apoptosis of hepatic stellate cells to suppress PDGF-BB-induced activation
por: Chen, Zhiwei, et al.
Publicado: (2019)

Gastroprotective Effects of Astragaloside IV against Acute Gastric Lesion in Rats
por: Mao, Shuai, et al.
Publicado: (2016)

Roles and Mechanisms of Astragaloside IV in Combating Neuronal Aging
por: Zaman, Qumar, et al.
Publicado: (2022)

Effects of Astragaloside IV on heart failure in rats
por: Zhao, Zhuanyou, et al.
Publicado: (2009)

Effects of astragaloside IV on the pharmacokinetics of omeprazole in rats
por: Liu, Wei, et al.
Publicado: (2019)

Astragaloside IV, as a potential anticancer agent
por: Xia, Dongqin, et al.
Publicado: (2023)

Pharmacological Effects of Astragaloside IV: A Review
por: Liang, Yutong, et al.
Publicado: (2023)

Astragaloside IV ameliorates acute pancreatitis in rats by inhibiting the activation of nuclear factor-κB
por: QIU, LEI, et al.
Publicado: (2015)

Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-κB/NLRP3 Axis
por: He, Jiaxin, et al.
Publicado: (2023)

Review on the protective mechanism of astragaloside IV against cardiovascular diseases
por: Yang, Chunkun, et al.
Publicado: (2023)

Astragaloside IV Targets Macrophages to Alleviate Renal Ischemia-Reperfusion Injury via the Crosstalk between Hif-1α and NF-κB (p65)/Smad7 Pathways
por: Tang, Lumin, et al.
Publicado: (2022)

Astragaloside IV represses high glucose-induced mesangial cells activation by enhancing autophagy via SIRT1 deacetylation of NF-κB p65 subunit
por: Wang, Xiaolei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6rtc28t6s32s9is2b9oav2q47q